Kliniczne wskaźniki dziedzicznych przyczyn i obciążenia leczeniem w opornej ogniskowej epilepsji: Kto najbardziej skorzysta z sekwencjonowania całego egzomu?

PubMed➕ 21.11.2026Epilepsy Behav

Clinical predictors of monogenic aetiology and pharmacotherapy burden in drug-resistant focal epilepsy: Who benefits most from whole exome sequencing?

W skrócie

Badacze sprawdzili, czy można przewidzieć, u których pacjentów z oporną ogniskową epilepsją przyczyna jest genetyczna, używając sekwencjonowania DNA. Okazało się, że zwykłe objawy choroby (wiek pojawienia się, częstość napadów, problemy z rozwojem) nie pozwalają dobrze przewidzieć, czy przyczyną jest mutacja genetyczna, dlatego trudno wskazać, którzy pacjenci powinni przejść drogim testem genetycznym. Liczba leków potrzebnych do kontroli napadów zależała od zaburzeń intelektualnych i częstości napadów, a nie od wyników testu genetycznego.

Oryginalny abstract (angielski)

BACKGROUND: Whole exome sequencing (WES) is of diagnostic value in focal drug-resistant epilepsy (FDRE) but is costly and not universally available. Identifying the clinical, imaging and electrophysiological features that predict a monogenic aetiology - and the determinants of pharmacotherapy burden - would allow rational selection of candidates for testing. We addressed both questions in a well-phenotyped Indian FDRE cohort. METHODS: One hundred and twenty-five patients with ILAE-defined FDRE underwent phenotyping and proband WES. Variants of uncertain significance (VUS) were re-evaluated against ACMG/AMP combining rules. Patients with a pathogenic or likely pathogenic (P/LP) variant (n = 12) were compared with WES-negative patients (n = 84); patients with only VUS (n = 29) were considered undiagnosed and described separately. Groups were compared using the Mann-Whitney U test (epilepsy-related variables) and Fisher's exact test (categorical features). Multiple linear regression identified independent predictors of the number of concurrent anti seizure medications (ASMs), and multivariable Firth-penalised logistic regression examined predictors of a P/LP diagnosis; effect sizes accompanied univariable associations. RESULTS: After reclassification, WES identified a P/LP variant in 12 patients (9.6 %); a further 29 (23.2 %) carried only VUS. No epilepsy-related variable (age of onset, epilepsy duration, seizure frequency, seizure-free interval, or ASM count) differed between P/LP and WES-negative patients. No categorical feature differed significantly: abnormal developmental history (42 % vs 21 %; OR 2.62, p = 0.152), positive family history (33 % vs 21 %; OR 1.83, p = 0.462) and intellectual deficits (25 % vs 15 %; OR 1.82, p = 0.415) were numerically more frequent in P/LP patients. Diagnostic yield was 14.7 % with abnormal development and 12.5 % with a positive family history, versus 7.7 % and 8.6 % in their absence. The number of concurrent ASMs was independently predicted by intellectual deficit (β = 0.813, p = 0.002) and log seizure frequency (β = 0.192, p = 0.030), but not by a P/LP variant (β = - 0.377, p = 0.261) or a VUS (β = - 0.316, p = 0.192). ASM adverse effects were infrequent (15/125) and unrelated to genetic status. CONCLUSIONS: Clinical presentation does not reliably distinguish patients with a P/LP diagnosis from WES-negative patients with FDRE. Abnormal development, family history and intellectual disability showed only non-significant enrichment of diagnostic yield in this P/LP group and require validation in larger cohorts. Pharmacotherapy burden was associated with intellectual disability and seizure frequency but was not explained by WES results.

Metadane publikacji

Journal
Epilepsy Behav
Data publikacji
20.11.2026
PMID
43063608
DOI
10.1016/j.yebeh.2026.111372
Autorzy
Chatterjee T, Panda S, Tiwari S, Kumar R
Słowa kluczowe
Drug-resistant epilepsy, Genotype–phenotype, Intellectual disability, Whole exome sequencing
Źródło
PubMed